ERBB2 and carcinoma: Trastuzumab (anti-Her2 antibody) is present in the pharmaceutical market having only 3% Her2-positive immunostaining across human carcinomas, with frequencies ranging from 0.4% in hepatocellular carcinoma to 12.4% in bladder cancer27.